Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Abstract CT091: Phase I study of intraperitoneal TRX-E-002-1 in patients with persistent or recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer: Results of dose-escalation phase

10.1158/1538-7445.am2019-ct091 ◽

2019 ◽

Author(s):

Jermaine Coward ◽

Don Dizon ◽

Ganessan Kichenadasse ◽

Paul Harnett ◽

Kathleen Moore ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Fallopian Tube ◽

Dose Escalation ◽

Phase I Study ◽

Recurrent Ovarian Cancer ◽

Fallopian Tube Cancer ◽

Abstract CT091: Phase I study of intraperitoneal TRX-E-002-1 in patients with persistent or recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer: Results of dose-escalation phase

10.1158/1538-7445.sabcs18-ct091 ◽

2019 ◽

Author(s):

Jermaine Coward ◽

Don Dizon ◽

Ganessan Kichenadasse ◽

Paul Harnett ◽

Kathleen Moore ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Fallopian Tube ◽

Dose Escalation ◽

Phase I Study ◽

Recurrent Ovarian Cancer ◽

Fallopian Tube Cancer ◽

OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer

10.1136/ijgc-2021-igcs.24 ◽

2021 ◽

Author(s):

F Backes ◽

J Fowler ◽

L Copeland ◽

L Wei ◽

D O’Malley ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase I Study ◽

Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-06-2664 ◽

2007 ◽

Vol 13 (13) ◽

pp. 4026.1-4026

Author(s):

Birgit C. Schultes ◽

L. Mary Smith ◽

Christopher F. Nicodemus

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase I Study ◽

A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

10.1200/jco.2015.33.15_suppl.5507 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5507-5507 ◽

Cited By ~ 15

Author(s):

Katherine M. Bell-McGuinn ◽

William E Brady ◽

Russell J. Schilder ◽

Paula M Fracasso ◽

Kathleen N. Moore ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase I Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Newly Diagnosed ◽

Oncology Group ◽

Oncology Group Study ◽

Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse (NCT01281514).

10.1200/jco.2018.36.15_suppl.5580 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5580-5580

Author(s):

Lainie P. Martin ◽

Angela Jain ◽

Christina Chu ◽

Gina Mantia-Smaldone ◽

Stephen C. Rubin ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase I Study ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Peritoneal Cancer ◽

Platinum Sensitive ◽

First Relapse

Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00771-x ◽

2021 ◽

Vol 162 ◽

pp. S68-S69

Author(s):

Floor Backes ◽

Lai Wei ◽

Larry Copeland ◽

David Cohn ◽

Jeffrey Fowler ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Phase I Study ◽

Peritoneal Cancer ◽

Platinum Resistant

Phase I study of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with pegylated liposomal doxorubicin in recurrent or persistent epithelial ovarian, Fallopian tube, or primary peritoneal cancer patients: An NRG/GOG study.

10.1200/jco.2015.33.15_suppl.5541 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5541-5541 ◽

Cited By ~ 5

Author(s):

Premal H. Thaker ◽

William E Brady ◽

William Hampton Bradley ◽

Khursheed Anwer ◽

Ronald David Alvarez

Keyword(s):

Phase I ◽

Cancer Patients ◽

Fallopian Tube ◽

Phase I Study ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Phase I study of intraperitoneal TRX-E-002-1 in subjects with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer: Three-month follow-up results of the dose escalation phase

Annals of Oncology ◽

10.1093/annonc/mdz250.042 ◽

2019 ◽

Vol 30 ◽

pp. v422-v423

Author(s):

J. Coward ◽

G. Kichenadasse ◽

P. Harnett ◽

K. Moore ◽

M. Barve ◽

...

Keyword(s):

Phase I ◽

Fallopian Tube ◽

Dose Escalation ◽

Phase I Study ◽

Phase I trial of the anti-idiotypic monoclonal antibody (mAb) ACA-125 in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer

10.1200/jco.2004.22.90140.5018 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5018-5018

Author(s):

P. Sabbatini ◽

C. Aghajanian ◽

J. Dupont ◽

F. Derosa ◽

S. Anderson ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Fallopian Tube ◽

Phase I Trial ◽